Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

• DOI: 10.1200/jco.2007.14.3529
• Publication Date: 2008-01-03T02:00:21Z
• Authors: Regina V. Tse; Maria Hawkins; Gina Lockwood; John J. Kim; Bernard Cummings; Jennifer Knox; Morris Sherman; Laura A. Dawson
• Keywords: Adult; Aged, 80 and over; Male; Carcinoma, Hepatocellular; Liver Neoplasms; Radiotherapy Dosage; Middle Aged; Radiosurgery; 3. Good health; Cholangiocarcinoma; Survival Rate; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Humans; Female; Gastrointestinal Hemorrhage; Radiation Injuries; Intestinal Obstruction; Aged

Purpose To report outcomes of a phase I study of individualized stereotactic body radiotherapy treatment (SBRT) for unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). Patients and Methods Patients with unresectable HCC or IHC, and who are not suitable for standard therapies, were eligible for six-fraction SBRT during 2 weeks. Radiation dose was dependent on the volume of liver irradiated and the estimated risk of liver toxicity based on a normal tissue complication model. Toxicity risk was escalated from 5% to 10% and 20%, within three liver volume–irradiated strata, provided at least three patients were without toxicity at 3 months after SBRT. Results Forty-one patients with unresectable Child-Pugh A HCC (n = 31) or IHC (n = 10) completed six-fraction SBRT. Five patients (12%) had grade 3 liver enzymes at baseline. The median tumor size was 173 mL (9 to 1,913 mL). The median dose was 36.0 Gy (24.0 to 54.0 Gy). No radiation-induced liver disease or treatment-related grade 4/5 toxicity was seen within 3 months after SBRT. Grade 3 liver enzymes were seen in five patients (12%). Two patients (5%) with IHC developed transient biliary obstruction after the first few fractions. Seven patients (five HCC, two IHC) had decline in liver function from Child-Pugh class A to B within 3 months after SBRT. Median survival of HCC and IHC patients was 11.7 months (95% CI, 9.2 to 21.6 months) and 15.0 months (95% CI, 6.5 to 29.0 months), respectively. Conclusion Individualized six-fraction SBRT is a safe treatment for unresectable HCC and IHC.